More Than Just Risk: Genetic Testing Is Shaping Breast Cancer Treatment

https://investor.myriad.com/news-releases/news-release-detail/11816/

Myriad and AstraZeneca Expand Research Collaboration on Lynparza

Apr 1, 2015 ... ... BRCA1/2 who may be appropriate for treatment with Lynparza. The approval of BRACAnalysis CDx was the first time the FDA has approved a ...

https://myriad.com/gene-table/

Gene Table | Myriad Genetics

BRCA1 · BRCA2 · BRIP1 · CDH1 ... BRCA1-associated Hereditary Breast And Ovarian Cancer Syndrome. BRCA2-associated Hereditary Breast And Ovarian Cancer Syndrome.

https://investor.myriad.com/news-releases/news-release-detail/21941/

Myriad Genetics Receives Additional Reimbursement for myChoice ...

... BRCA1 and BRCA2. It enables healthcare professionals to identify patients with advanced ovarian cancer who are eligible for first-line maintenance treatment ...

https://investor.myriad.com/news-releases/news-release-detail/20291/

Myriad Applauds the American Society of Breast Surgeons New ...

Feb 15, 2019 ... The National Cancer Institute estimates that 35,000 patients with breast cancer have pathogenic BRCA1/2 mutations, but only 30 percent have been ...

https://investor.myriad.com/news-releases/news-release-detail/21181/

Myriad Receives FDA Approval of BRACAnalysis CDx® as a ...

May 20, 2020 ... BRACAnalysis CDx is the only FDA-approved germline test to identify men with BRCA1 and BRCA2 mutations, a subpopulation of HRR gene mutations.

https://investor.myriad.com/news-releases/news-release-detail/20981/

Myriad Submits sPMA for myChoice® CDx with Zejula® in First-Line ...

Patients with certain characteristics such as a family history of the disease, certain genetic mutations such as those in the BRCA1 and BRCA2 genes, obesity ...

https://investor.myriad.com/news-releases/news-release-detail/10851/

Myriad Presents Clinical Data on Myriad myRisk™ Hereditary ...

Jun 2, 2014 ... ... BRCA1 and BRCA2 testing alone. Analysis of patients with two hereditary cancers (breast/ovarian or colon/endometrial) who met NCCN genetic ...

https://investor.myriad.com/news-releases/news-release-detail/21286/

News Release - Investor relations - Myriad Genetics

It showed that independent of other hereditary breast cancer gene mutations (e.g., BRCA1) ... The study demonstrated that patients with high penetrant genes such ...

https://investor.myriad.com/news-releases/news-release-detail/12301/

Myriad's BRACAnalysis CDx® Test Successfully Identified ...

Feb 17, 2017 ... Of the 302 patients in the study, 98 percent (297/302) tested positive for germline BRCA1/2 mutations as determined by Myriad's FDA-approved ...

https://investor.myriad.com/news-releases/news-release-detail/19911/

Myriad Announces New Laboratory Agreement with Pfizer®

... BRCA1 and BRCA2 genes using genomic DNA obtained from whole blood specimens collected in EDTA. Single nucleotide variants and small insertions and deletions ...